Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Frank E.H.P. van Baarle et al.|The Lancet Rheumatology|2020Cited by 199
Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infectionLihui Guo, Robert Hemke, Brent Appelman et al.|EBioMedicine|2023Cited by 38
Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general wardJustin de Brabander, Menno D. de Jong, Erik H.A. Michels et al.|Respiratory Research|2022Cited by 9
Endothelial Permeability and the Angiopoietin/Tie2 System Following Mild and Severe COVID-19Carolien Volleman, Niels van Mourik, Roselique Ibelings et al.|Artery Research|2023Cited by 4